Compliance & Validation — Documented
ISO 27001, SOC 2 Type II
Schrodinger
Physics-based computational platform for drug discovery and materials design, augmented by ML.
Schrodinger provides a comprehensive suite of physics-based simulation and machine learning tools for drug discovery. Their platform spans molecular dynamics, free energy perturbation calculations, and AI-driven lead optimization, used by major biopharma companies to reduce the time and cost of bringing new medicines to market.
- Headquarters
- New York, United States
- Founded
- 1990
- Compliance
- ISO 27001, SOC 2 Type II
- Deployment options
- cloud, on-premise, private-cloud
- Website
- https://www.schrodinger.com
- https://www.linkedin.com/company/schr-dinger
Categories
AI Use Cases
- ADMET & Toxicity Prediction
- Hit Identification & Lead Optimization
- Manufacturing Process Optimization
Vendor Scorecard
100% — Complete coverage. Coverage score — how completely Atlas documents Schrodinger across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud, on premise, private cloud
Pricing Transparency — Documented
Annual subscription by module
Implementation & Onboarding — Documented
3–6 months
Organization & Role Fit — Documented
Mid-Size Biotech, Large Pharma, Top 20 Pharma, Drug Discovery
Solution Scope — Documented
ADMET Prediction, Molecular Generation, Protein Structure Prediction
Company Viability — Documented
Public, $200M raised, 700+ employees, Founded 1990
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Evidence & Outcomes
Nimbus TYK2 program (TAK-279) acquired by Takeda for $4 billion upfront
A selective TYK2 inhibitor discovered using Schrödinger's physics-based computational platform (developed by Nimbus Therapeutics) was acquired by Takeda for $4 billion upfront, demonstrating commercial validation of a computationally designed clinical asset.
press release (Nimbus Therapeutics) · 2022-12-13 — Partner: Nimbus Therapeutics / Takeda
Questions to Ask This Vendor
- What GPU infrastructure is required for FEP calculations at scale?
- How does LiveDesign integrate with our existing SAR databases?
- What training and onboarding is included in the license?